Related Experiment Videos
Potential methods to prevent interstitial fibrosis in renal disease
1Department of Nephrology and Rheumatology,Georg-August-University, Robert-Koch-Str. 40,37075 Göttingen, Germany. fstrutz@gwdg.de
Expert Opinion on Investigational Drugs
|January 5, 2002
Summary
New antifibrotic therapies show promise for treating progressive renal fibrosis in end-stage renal disease (ESRD). While current treatments manage symptoms, novel compounds offer hope for halting disease progression, though clinical application is still developing.
Area of Science:
- Nephrology
- Pathology
- Pharmacology
Background:
- End-stage renal disease (ESRD) is characterized by interstitial fibrosis and tubular atrophy.
- Inflammatory processes often initiate chronic renal failure, making early anti-inflammatory strategies potentially effective.
- Clinical detection frequently occurs after significant disease progression, limiting early intervention effectiveness.
Purpose of the Study:
- To review promising antifibrotic compounds for treating progressive renal fibrosis.
- To highlight agents with demonstrated in vitro and in vivo antifibrotic properties.
- To assess the current clinical evaluation status of these novel therapeutic agents.
Main Methods:
- Review of scientific literature on antifibrotic compounds.
- Analysis of in vitro and in vivo study data for efficacy.
- Assessment of the clinical trial status for promising candidates.
Main Results:
- Several compounds exhibit potent antifibrotic properties.
- Some agents are in early stages of clinical evaluation.
- Many promising compounds are still years away from clinical use.
Conclusions:
- Effective treatment for progressive renal fibrosis requires therapies beyond current standards like ACE inhibitors.
- Novel antifibrotic agents represent a potential future enhancement to the clinical management of ESRD.
- While many agents are in early development, some may become available relatively soon.